Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Active Biotech AB ( (SE:ACTI) ) has shared an announcement.
Active Biotech has received approval from European regulatory authorities and ethics committees to resume patient enrolment in the HOVON 172 MF proof‑of‑concept study of tasquinimod in myelofibrosis, conducted within the HOVON network in the Netherlands and Germany. The amendment, which introduces a more flexible dosing regimen aligned with prior prostate cancer trials, is expected to facilitate recruitment and support further clinical evaluation of tasquinimod in patients who are refractory or ineligible to JAK2 inhibitors.
The study, legally sponsored by HOVON and supported by Oncode Institute’s Clinical Proof‑of‑Concept programme, is part of a broader collaboration aimed at accelerating translation of promising cancer research into treatments for patients with limited therapeutic options. For Active Biotech, the restart of enrolment strengthens the clinical development of tasquinimod in a rare blood cancer with high unmet need, potentially enhancing its strategic position in hematology and immuno‑oncology if efficacy is confirmed.
More about Active Biotech AB
Active Biotech AB is a Swedish biotechnology company focused on developing first‑in‑class immunomodulatory therapies for oncology and immunology indications with high unmet medical need. Its core pipeline includes tasquinimod for myelofibrosis, laquinimod for non‑infectious uveitis in partnership for phase II development, and the anti‑cancer immunotherapy naptumomab, which is partnered with NeoTX Therapeutics.
YTD Price Performance: 34.78%
Average Trading Volume: 30,164,429
Technical Sentiment Signal: Sell
Current Market Cap: SEK165.5M
Find detailed analytics on ACTI stock on TipRanks’ Stock Analysis page.